1401 Foch Street
About Actuate TherapeuticsActuate Therapeutics is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
Actuate was founded in 2015 with a mission of discovering, developing, and commercializing new agents that target GSK-3ß, based on intellectual capital developed in the laboratories of the University of Illinois-Chicago and Northwestern University. The company is led by a senior management and scientific team with decades of pharmaceutical industry experience leading successful discovery, development, and commercialization of new therapeutic agents and health related technologies.
President & CEO: Daniel M. Schmitt
CMO: Francis J. Giles, MB, MD, FRCPI, FRCPath
Co-Founder & Chief Scientific Advisor: Andrew P. Mazar, Ph.D.
Consulting Scientific Director: Andrey Ugolkov (Ougolkov), M.D., Ph.D.
Please click here for Actuate Therapeutics' research.
8 articles with Actuate Therapeutics
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.
The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round.
ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors.
The clinical trial will be initiated in over 20 world-leading oncology research institutions in the EU and US after successful regulatory reviews of the application.
Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma
The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,